Annotated Patent Selections

Bibliography

• GALLI SJ: New concepts about the mast cell. New Engl. I Med. (1993) 328:257–265.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive review concerning the basic features ofmast cells and their new and extended biological role be-yond 'simple troublemakers' in allergic conditions.
   Google Scholar
• GORDON JR, GALLI SJ: Mast cells as a source of both pre-fomed and immunologically inducible TNF-a/cachec-tin. Nature (1990) 346:274–276.
   PubMed Web of Science ®Google Scholar
• GORDON JR, BURD PR, GALLI SJ: Mast cells as a source of multifunctional cytokines. Immunol. Today (1990) 11:458–464.
   PubMedGoogle Scholar
• GALLI SJ: The Paul Kallos Memorial Lecture. The mast cell: a versatile effector cell for a challenging world. Int. Arch. Allergy Immunol. (1997) 113:14–22.
   Google Scholar
• TSAI M, TAKEISHI T, THOMPSON H et al.: Induction of mast cell proliferation, maturation, and heparin syn-thesis by the rat c-kit ligand, stem cell factor. Proc. Natl. Acad. Sci. USA (1991) 88:6382–6386.
   PubMed Web of Science ®Google Scholar
• LOUAHED J, KERMOUNI A, VAN SNICK J et al.: IL-9 in-duces expression of granzymes and high-affinity IgE receptor in murine T helper clones. J. Immunol. (1995) 154:5061–5070.
   Google Scholar
• WANG B, RIEGER A, KILGUS 0 et al.: Epidermal Langer-hans cells from normal human skin bind monomeric IgE via Fc epsilon RI. J. Exp. Med. (1992) 175:1353–1365.
   Google Scholar
• MAURER D, FIEBIGER E, REININGER B et al: Expression of functional high affinity immunoglobulin E recep-tors (Fc epsilon RD on monocytes of atopic individu-als. J. Exp. Med. (1994) 179:745–750.
   PubMed Web of Science ®Google Scholar
• MAURER D, FIEBIGER S, EBNER C et al.: Peripheral blood dendritic cells express Fc epsilon RI as a complex com-posed of Fc epsilon RI alpha- and Fc epsilon RI gamma-chains and can use this receptor for IgE-mediated allergen presentation. J. Immunol. (1996) 157:607–616.
   PubMed Web of Science ®Google Scholar
• OCHIAI K, WANG B, RIEGER A et al: A review on Fc epsi-lon RI on human epidermal Langerhans cells. Int. Arch. Allergy Immunol (1994) 104 (Suppl. 0:63–64.
   Google Scholar
• NAGATA H, WOROBEC AS, OH CK et al.: Identification ofa point mutation in the catalytic domain of the pro-tooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associ-ated hematologic disorder. Proc. Natl. Acad. ScL USA (1995) 92:10560–10564.
   PubMed Web of Science ®Google Scholar
• KINET JP: The high-affinity receptor for IgE. Curr. Opin. Immunol (1989) 2:499–505.
   PubMed Web of Science ®Google Scholar
• RAVETCH JV, KINET JP: Fc Receptors. Ann. Rev. Immu-nol. (1991) 9:457–492.
   PubMed Web of Science ®Google Scholar
• JOUVIN ME, ADAMCZEWSKI M, NUMEROF R et al.: Differ-ential control of the tyrosine kinases lyn and syk by two signaling chains of the high affinity immuno-globulin E receptor. J. Biol. Chem. (1994) 269:5918-5925. An elegant biochemical study elucidating the sequential in-teraction of the tetrameric FcERI complex (primarily the 13 and y chain) with the two essential kinases Lyn and Syk to form the multimeric receptor/kinase complex required for initiating the allergic response.
   Google Scholar
• SHIUE L, GREEN J, GREEN OM et al.: Interaction of p72syk with the gamma and beta subunits of the high-affinity receptor for immunoglobulin E, Fc epsilon RI. Mol. Cell Biol. (1995) 15:272–281.
   PubMed Web of Science ®Google Scholar
• JABRIL CUENOD B, ZHANG C, SCHARENBERG AM et al.: Syk-dependent phosphorylation of Shc. A potential link between Fc epsilon RI and the Ras/mitogen-activated protein kinase signaling pathway through SOS and Grb2../. Biol. Chem. (1996) 271:16268–16272.
   Google Scholar
• UN S, CICALA C, SCHARENBERG AM et al.: The Fc(epsi-lon) RI beta subunit functions as an amplifier of Fc(ep-silon)RI gamma-mediated cell activation signals. Cell (1996) 85:985–995.
   PubMed Web of Science ®Google Scholar
• ••The clarification of the function of the 13 chain which helpsto understand why the FcERI exists either as a ocy2 trimer or an c43y2 tetramer.
   Google Scholar
• SCHARENBERG AM, UN S, CUENOD B et al.: Reconstitution of interactions between tyrosine kinases and the high affinity IgE receptor which are controlled by re-ceptor clustering. EMBO J. (1995) 14:3385–3394.
   PubMed Web of Science ®Google Scholar
• •The first reconstitution of a functional FcERI/Lyn/Syk recep-tor/kinase complex in a non-hematopoetic 'null' cell line, using a vaccinia driven protein expression system.
   Google Scholar
• KAWAKAMI Y, YAO L, TASHIRO M et al.: Activation andinteraction with protein kinase C of a cytoplasmic ty-rosine kinase, Itk/Tsk/Emt, on Fc epsilon RI cross-linking on mast cells. J. Immunol (1995) 155:3556–3562.
   PubMed Web of Science ®Google Scholar
• PRICE DJ, KAWAKAMI Y, KAWAKAMI T et al: Purificationof a major tyrosine kinase from RBL-2113 cells phos-phorylating Fc epsilon RI gamma-cytoplasmic domain and identification as the Btk tyrosine kinase. Biochim. Biophys. Acta (1995) 1265:133–142.
   PubMedGoogle Scholar
• BEAVEN MA, MOORE JP, SMITH GA et al.: The calciumsignal and phosphatidylinositol breakdown in 2113 cells. J. Biol. Chem. (1984) 259:7137–7142.
   PubMed Web of Science ®Google Scholar
• OZAWA K, SZALLASI Z, KAZANIETZ MG et al.: Ca(2+)-d-ependent and Ca(2+)-independent isozymes of pro-tein kinase C mediate exocytosis in antigen-stimulated rat basophilic RBL-2113 cells. Reconstitution of secre-tory responses with Ca2+ and purified isozymes in washed permeabilized cells. J. Biol. Chem. (1993) 268:1749–1756.
   Google Scholar
• CHOI OH, KIM JH, KINET JP: Calcium mobilization viasphingosine kinase in signalling by the Fc epsilon RI antigen receptor. Nature (1996) 380:634–636.
   PubMed Web of Science ®Google Scholar
• ISHIZUKA T, TERADA N, GERWINS P et al: Mast cell tu-mor necrosis factor a production is regulated by MEK kinases. Proc. Natl. Acad. ScL USA (1997) 94:6358–6363.
   PubMed Web of Science ®Google Scholar
• ZHANG C, BAUMGARTNER RA, YMADA K et al.: Mitogen-activated protein (MAP) kinase regulates production of tumor necrosis factor-a and release of arachidonic acid in mast cells. J. Biol. Chem. (1997) 272:13397–13402.
   PubMed Web of Science ®Google Scholar
• CSONGA R, PRIESCHL EE, JAKSCHE D et al: Common anddistinct signaling pathways mediate the induction of TNFa and IL-5 in IgE plus antigen stimulated mast cells. Immunol (1998) 160:273–283.
   Web of Science ®Google Scholar
• •The demonstration that different cytokines are regulated along different and common signalling cascades, giving rise to the notion that "cytokine specific" inhibitors for mast cells can be found.
   Google Scholar
• YANO H, NAKANISHI S, KIMURA K et al.: Inhibition ofhistamine secretion by wortmannin through the blockade of phosphatidylinositol 3-kinase in RBL-3113 cells. J. Biol. Chem. (1993) 268:25846–25852.
   PubMed Web of Science ®Google Scholar
• PENDL GG, PRIESCHL EE, HARRER NE et al.: Effects ofphosphatidylinosito1-3-kinase inhibitors on degranu-lation and gene induction of allergically triggered mouse mast cells. Int. Arch. Allergy Immunol. (1997) 112:392–399.
   PubMed Web of Science ®Google Scholar
• MARQUARDT DL, ALONGI JL, WALKER LL: The phospha-tidylinositol 3-kinase inhibitor wortmannin blocks mast cell exocytosis but not IL-6 production. J. Immu-nol. (1996) 156:1942–1945.
   PubMed Web of Science ®Google Scholar
• RAZIN E, SZALLASI Z, KAZANIETZ MG et al.: Protein ki-nase c-p and C-6 link the mast cell high-affinity recep-tor for IgE to the expression of c-fos and c-jun. Proc. Natl Acad. Sci. USA (1994) 91:7722–7726.
   PubMed Web of Science ®Google Scholar
• •A clear link of the involvement of certain PKC isoforms and E, but not a and 8) in the allergic signalling cascades in mast cells after FcERI triggering.
   Google Scholar
• BARANES D, RAZIN E: Protein kinase C regulates prolif-eration of mast cells and the expression of the mRNAs of fos and jun proto-oncogenes during activation by IgE-Ag or calcium ionophore A23187. Blood (1991) 78:2354–2364.
   PubMed Web of Science ®Google Scholar
• LEWIS RA, AUSTEN KF, SOBERMAN RJ: Leukotrienes andother products of the 5-lipoxygenase pathway - bio-chemistry and relation to pathobiology in human dis-eases. New Engl. J. Med. (1990) 323:645–655.
   PubMed Web of Science ®Google Scholar
• PRIESCHL EE, GOUILLEUX-GRUART V, WALKER C et al:An NFAT like transcription factor on mast cells is in-volved in 115 gene regulation after IgE plus Ag stimula-tion. J. Immunol. (1995) 154:6112–6119.
   PubMed Web of Science ®Google Scholar
• •The first description of NF-AT expression and function in mast cells, explaining why drugs like CsA and FK506 abbro-gate the cytokine response in this cell type and are clinically beneficial.
   Google Scholar
• WEISS DL, HURAL J, TARA D et al.: Nuclear factor of acti-vated T-cells is associated with a mast cell interleukin 4 transcription complex. Mol. Cell Biol. (1996) 16:228–235.
   PubMed Web of Science ®Google Scholar
• HEUSSER C, JARDIEU P: Therapeutic potential of anti-IgE antibodies. Curr. Opin. Immunol. (1997) 9:805–813.
   PubMed Web of Science ®Google Scholar
• •A very well written history on anti IgE antibodies by the two scientists involved in the validation of the therapeutic princi-ple and bringing it to Phase II clinical trials.
   Google Scholar
• MACGLASHAN DW, Jr., BOCHNER BS, ADELMAN DC et al.: Down-regulation of Fc (epsilon)RI expression on hu-man basophils during in vivo treatment of atopic patients with anti-IgE antibody. J. Immunol. (1997) 158:1438–1445.
   Google Scholar
• CHANG TW, DAVIS FM, SUN NC et al.: Monoclonal anti-bodies specific for human IgE-producing B cells: a po-tential therapeutic for IgE-mediated allergic diseases. Biotechnology NY (1990) 8:122–126.
   PubMedGoogle Scholar
• RUDOLF MP, VOGEL M, KRICEK F et al: Epitope-specific antibody response to IgE by mimotope immunization. Immunol. (1998) 160:3315–3321.
   Web of Science ®Google Scholar
• •An interesting paper expanding the field of vaccination, not only from the theoretical - but also experimental side.
   Google Scholar
• FRIGERI LG, LIU FT: Surface expression of functional IgE binding protein, an endogenous lectin, on mast cells and macrophages. J. Immunol (1992) 148:861–867.
   PubMed Web of Science ®Google Scholar
• WIEGAND TW, WILLIAMS PB, DRESKIN SC et al.: High-affinity oligonucleotide ligands to human IgE inhibit binding to Fc epsilon receptor I. J. Immunol. (1996) 157:221–230.
   PubMed Web of Science ®Google Scholar
• SLATER JE, BOLTANSKY H, KALINER M: IgE immunotox-ins. Effect of an IgE-ricin A chain conjugate on rat skin histamine content. J. Immunol (1988) 140:807–811.
   Google Scholar
• BOLTANSKY H, DYER J, ESWORTHY S et al.: IgE-immunotoxins. I. IgE-intact ricin. Immunopharmacol-ogy (1987) 14:35–45.
   PubMedGoogle Scholar
• FISHMAN A, LORBERBOUM GALSKI H: Targeted elimina-tion of cells expressing the high-affinity receptor for IgE (Fc epsilon RI) by a Pseudomonas exotoxin-based chimeric protein. Eur. j Immunol. (1997) 27:486–494.
   PubMed Web of Science ®Google Scholar
• KATZ HR, AUSTEN KF: A newly recognized pathway for the negative regulation of mast cell-dependent hyper-sensitivity and inflammation mediated by an endoge-nous cell surface receptor of the gp49 family. J. Immunol. (1997) 158:5065–5070.
   PubMed Web of Science ®Google Scholar
• CASTELLS MC, WU X, ARM JP et al.: Cloning of the gp49B gene of the immunoglobulin superfamily and demon-stration that one of its two products is an early-expressed mast cell surface protein originally de-scribed as gp49. J. Biol. Chem. (1994) 269:8393–8401.
   PubMed Web of Science ®Google Scholar
• ADRA CN, LELIAS JM, KOBAYASHI H et al: Cloning of the cDNA for a hematopoietic cell-specific protein related to CD20 and the beta subunit of the high-affinity IgE re-ceptor: evidence for a family of proteins with four membrane-spanning regions. Proc. Natl. Acad. Sci. USA (1994) 91:10178–10152.
   PubMed Web of Science ®Google Scholar
• HIEBLE JP, BONDINELL WE, RUFFOLO RRR: Alpha- and beta- adrenoceptors: from the gene to the clinic. 1. Mo-lecular biology and adrenoceptor subclassification. J. Med. Chem. (1995) 38:3415–3444.
   Google Scholar
• ••An comprehensive review of adrenoceptors, as an excellentstart for newcomers in this field.
   Google Scholar
• RUFFOLO RRR, BONDINELL WE, HIEBLE JP: Alpha- and beta- adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic appli-cation. J. Med. Chem. (1995) 38:3681–3716.
   Google Scholar
• ••The second part of [47] with a detailed insight into SAR andtherapeutic applications of currently available compounds.
   Google Scholar
• CHONG LK, COOPER E, VARDEY CJ eta].: Salmeterol in-hibition of mediator release from human lung mast cells by beta-adrenoceptor-dependent and independ-ent mechanisms. Br. J. Pharmacol. (1998) 123:1009–1015.
   Google Scholar
• BISSONNETTE EY, BEFUS AD: Anti-inflammatory effect of beta 2-agonists: inhibition of TNF-alpha release from human mast cells. J. Allergy Clin. Immunol. (1997) 100:825–831.
   PubMed Web of Science ®Google Scholar
• LAU HY, WONG PL, LAI CK: Effects of beta 2-adrenergic agonists on isolated guinea pig lung mast cells. Agents Actions (1994) 42:92–94.
   PubMedGoogle Scholar
• OHKUBO T, SHIBATA M, INOUE M et al.: Autoregulation of histamine release via the histamine 113 receptor on mast cells in the rat skin. Arch. Int. Pharmacodyn. Ther. (1994) 328:307–314.
   PubMedGoogle Scholar
• PATELLA V, DE CRESCENZO G, MARINO 0 et al.: Oxato-mide inhibits the release of proinflammatory media-tors from human basophils and mast cells. mt. Arch. Allergy Immunol. (1996) 111:23–29.
   Google Scholar
• BISSONNETTE EY: Histamine inhibits tumor necrosis factor alpha release by mast cells through 112 and 113 receptors. Am. J. Respir. Cell Mot Biol. (1996) 14:620–626.
   PubMed Web of Science ®Google Scholar
• PAULUSSEN JJ, FISCHER MJ, KOK VAN ESTERIK JA et al.: Influence of the anti-allergic drug oxatomide on the signal transduction mechanism in a mast cell model. Eur. Pharmacol. (1996) 312:121–130.
   Google Scholar
• PAULUSSEN JJ, FISCHER MJ, ROELOFSEN EP et al.: Oxato-mide and derivatives as inhibitors of mediator release from a mast cell model. Structure-activity relation-ships. Arzneim.-Forschung (1996) 46:496–501.
   Google Scholar
• BEAVEN MA, RAMKUMAR V, ALI H: Adenosine A3 recep-tors in mast cells. Trends Pharmacol. Sci. (1994) 15:13–14.
   PubMed Web of Science ®Google Scholar
• RAMKUMAR V, STILES GL, BEAVEN MA et al.: The A3adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells. J. Biol. Chem. (1993) 268:16887–16890.
   PubMed Web of Science ®Google Scholar
• •An interesting receptor study, addressing the function and importance of the A3 receptor on RBL-2H3 cells, and its po-tential as a new molecular target.
   Google Scholar
• JACOBSON KA: Adenosine A3 receptors: novel ligands and paradoxical effects. Trends Pharmocol. Sci. (1998) 19:184–191.
   PubMed Web of Science ®Google Scholar
• ••A lucid review dealing with the still to be solved mysteriessurrounding the contribution of the A3 receptor to the trig-gering of mast cells.
   Google Scholar
• WALKER BA, JACOBSON MA, KNIGHT DA et al.: Adeno-sine A3 receptor expression and function in eosino-phils. Am. J. Respir. Cell Mot Biol. (1997) 16:531–537.
   PubMed Web of Science ®Google Scholar
• MEADE CJ, MIERAU J, LEON I et al.: In vivo role of theadenosine A3 receptor: N6-2(4-aminopheny0 ethy-ladenosine induces bronchospasm in BDE rats by a neurally mediated mechanism involving cells resem-bling mast cells. J. Pharmacol. Exp. Ther. (1996) 279:1148–1156.
   PubMed Web of Science ®Google Scholar
• MORIYA K, RIVERA J, ODOM S et al.: ER-27319, anacridone-related compound, inhibits release of antigen-induced allergic mediators from mast cells by selective inhibition of Fc epsilon receptor I-mediated activation of Syk. Proc. Natl. Acad. Sci. USA (1997) 94:12539–12544.
   PubMed Web of Science ®Google Scholar
• OLIVER JM, BURG DL, WILSON BS et al.: Inhibition ofmast cell Fc epsilon R1-mediated signaling and effec-tor function by the Syk-selective inhibitor, piceatan-nol. J. Biol. Chem. (1994) 269:29697–29703.
   PubMed Web of Science ®Google Scholar
• LAVENS PHILLIPS SE, MOCKFORD EH, WARNER JA: Theeffect of tyrosine kinase inhibitors on IgE-mediated histamine release from human lung mast cells and ba-sophils. Inflamm. Res. (1998) 47:137–143.
   PubMed Web of Science ®Google Scholar
• SCHMIDT CHOUDHURY A, FURUTA GT, LAVIGNE JA etal.: The regulation of tumor necrosis factor-alpha pro-duction in murine mast cells: pentoxifylline or dex-amethasone inhibits IgE-dependent production of TNF-alpha by distinct mechanisms. Cell Immunol. (1996) 171:140–146.
   Google Scholar
• SCHICK B, AUSTEN KF: Modulation of chymase-mediated rat serosal mast cell degranulation by tryp-sin or diisopropyl fluorophosphate. Immunology (1989) 66:434–438.
   PubMed Web of Science ®Google Scholar
• SCHICK B, AUSTEN KF: Rat serosal mast cell degranula-tion mediated by chymase, an endogenous secretory granule protease: active site-dependent initiation at 1 degree C. J. Immunol. (1986) 136:3812–3818.
   PubMed Web of Science ®Google Scholar
• SCHICK B, AUSTEN KF, SCHWARTZ LB: Activation of ratserosal mast cells by chymase, an endogenous secre-tory granule protease. J. Immunol. (1984) 132:2571–2577.
   PubMed Web of Science ®Google Scholar
• UNANGST PC, CONNOR DT, CETENKO WA et at: Synthe-sis and biological evaluation of 543,5-bis(1,1-dimethylethy0-4-hydroxyphenyl[methylene]oxa-zoles, -thiazoles, and -imidazoles: novel dual 5-lipoxygenase and cyclooxygenase inhibitors with an-tiinflammatory activity. J. Med. Chem. (1994) 37:322–328.
   PubMed Web of Science ®Google Scholar
• •A straightforward medicinal chemistry approach targeting both the lipoxygenase and cycloxygenase pathway.
   Google Scholar
• SCHOLZ D, SCHMIDT H, PRIESCHL EE et al.: Inhibition of FceR I-mediated activation of mast cells by 2,3,4-trihydropyrimidino[2,1- a]isoquinolines. J. Med. Chem. (1998) 41:1050–1059.
   Google Scholar
• •The first description of relatively specific inhibitors of mast cell signalling with unknown mode of action but impressive in vivo function in a PCA.
   Google Scholar
• BARAM D, RASHKOVSKY M, HERSHKO VIZ R et al: Inhibi- tory effects of low molecular weight heparin on me-diator release by mast cells: preferential inhibition of cytokine production and mast cell-dependent cutane-ous inflammation. Clin. Exp. Immunol (1997) 110:485-491. Patents
   Google Scholar